Real world handling performance of fluticasone propionate/salmeterol HFA MDI with an integrated dose counter in subjects with asthma or COPD

C. Crim, W. R. Lincourt, K. K. Sheth, N. W. Locantore (Research Triangle Park, Lafayette, United States Of America)

Source: Annual Congress 2005 - Inhaler devices: challenges and solutions
Session: Inhaler devices: challenges and solutions
Session type: Thematic Poster Session
Number: 863
Disease area: Airway diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
C. Crim, W. R. Lincourt, K. K. Sheth, N. W. Locantore (Research Triangle Park, Lafayette, United States Of America). Real world handling performance of fluticasone propionate/salmeterol HFA MDI with an integrated dose counter in subjects with asthma or COPD. Eur Respir J 2005; 26: Suppl. 49, 863

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Efficacy and safety of new formulation of fluticasone propionate/salmeterol delivered via a HFA pMDI inhaler in patients with asthma
Source: Virtual Congress 2020 – Asthma inhalers: devices and adherence studies
Year: 2020


Comparison of a new HFA 134a-formulated budesonide pMDI with a standard CFC-formulated budesonide pMDI in children with persistent asthma
Source: Eur Respir J 2005; 26: Suppl. 49, 160s
Year: 2005

Patient satisfaction with fluticasone propionate/salmeterol (FSC) HFA with an integrated dose counter
Source: Eur Respir J 2005; 26: Suppl. 49, 127s
Year: 2005

The novel budesonide HFA pMDI is clinically comparable to the conventional budesonide CFC pMDI in paediatric patients with asthma
Source: Eur Respir J 2005; 26: Suppl. 49, 160s
Year: 2005

²Stepping down[/quot] from fluticasone propionate/salmeterol 100/50mcg Diskus® results in loss of asthma control
Source: Eur Respir J 2004; 24: Suppl. 48, 309s
Year: 2004

Comparison of HFA fluticasone-formoterol combination pressurized meter dose inhaler (pMDI) and HFA budesonide-formoterol combination pMDI in patients with moderate to severe persistent asthma
Source: Annual Congress 2010 - Drug delivery and pharmacokinetics II
Year: 2010


Low dose salmeterol/fluticasone propionate combination (SFC) via metered dose inhaler (MDI) improves asthma control and quality of life in patients not well controlled on inhaled steroids (ICS)
Source: Eur Respir J 2002; 20: Suppl. 38, 47s
Year: 2002

Efficacy of salmeterol/fluticasone propionate (50/100mcg/day) delivered via the Diskus™ and MDI in children with asthma
Source: Eur Respir J 2003; 22: Suppl. 45, 311s
Year: 2003

Budesonide/formoterol in a single inhaler once or twice daily provides better asthma control than inhaled fluticasone or budesonide alone in patients with moderate persistent asthma
Source: Eur Respir J 2002; 20: Suppl. 38, 387s
Year: 2002

Non inferiority comparison of salmeterol HFA (SM-HFA) pMDI with salmeterol CFC (SM-CFC) pMDI in patients with symptomatic asthma
Source: Eur Respir J 2007; 30: Suppl. 51, 357s
Year: 2007

Effectiveness and safety of fluticasone propionate/salmeterol 250/50mcg administered once daily to patients with persistent asthma
Source: Eur Respir J 2004; 24: Suppl. 48, 309s
Year: 2004

Achievement of total control of asthma in clinical practice using the combination of inhaled salmeterol and fluticasone propionate
Source: Eur Respir J 2006; 28: Suppl. 50, 616s
Year: 2006

Budesonide and formoterol in a single inhaler quickly gains asthma control compared with fluticasone propionate in mild asthma
Source: Eur Respir J 2001; 18: Suppl. 33, 48s
Year: 2001

Non-inferiority comparison of budesonide HFA (BUD-HFA) pMDI with budesonide CFC (BUD-CFC) pMDI in patients with persistent moderate asthma
Source: Annual Congress 2008 - Wider aspects of managing respiratory disease in primary care
Year: 2008


Efficacy of combined budesonide/formoterol delivered via turbuhaler on lung function and asthma control in asthmatic children
Source: Eur Respir J 2003; 22: Suppl. 45, 496s
Year: 2003

Budesonide HFA pMDI is pharmacokinetically and clinically comparable with budesonide CFC pMDI in healthy volunteers, and in adults and children with asthma
Source: Eur Respir J 2005; 26: Suppl. 49, 503s
Year: 2005

Cost-effectiveness of budesonide and formoterol in a single inhaler compared to fluticasone in the treatment of asthma
Source: Eur Respir J 2001; 18: Suppl. 33, 157s
Year: 2001

Efficacy and safety of fluticasone furoate (FF)/vilanterol (VI) compared with fluticasone propionate/salmeterol combination (FP/SAL) in adults and adolescents with persistent asthma
Source: Annual Congress 2012 - Trials in asthma: asthma exacerbations and severe asthma
Year: 2012

Performance of salmeterol/fluticasone propionate HFA MDIs with and without counter are comparable
Source: Eur Respir J 2005; 26: Suppl. 49, 126s
Year: 2005

Clinical equivalence of salmeterol/fluticasone propionate combination 50/100mcg b.i.d. delivered via DiskusÔ or CFC-free metered dose Inhaler (MDI) in children with asthma
Source: Eur Respir J 2003; 22: Suppl. 45, 311s
Year: 2003